These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11228361)

  • 1. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens.
    Hartikka J; Bozoukova V; Ferrari M; Sukhu L; Enas J; Sawdey M; Wloch MK; Tonsky K; Norman J; Manthorpe M; Wheeler CJ
    Vaccine; 2001 Feb; 19(15-16):1911-23. PubMed ID: 11228361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses.
    Sankar V; Baccaglini L; Sawdey M; Wheeler CJ; Pillemer SR; Baum BJ; Atkinson JC
    Oral Dis; 2002 Nov; 8(6):275-81. PubMed ID: 12477057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.
    Jimenez GS; Planchon R; Wei Q; Rusalov D; Geall A; Enas J; Lalor P; Leamy V; Vahle R; Luke CJ; Rolland A; Kaslow DC; Smith LR
    Hum Vaccin; 2007; 3(5):157-64. PubMed ID: 17637571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.
    Shlapobersky M; Marshak JO; Dong L; Huang ML; Wei Q; Chu A; Rolland A; Sullivan S; Koelle DM
    J Gen Virol; 2012 Jun; 93(Pt 6):1305-1315. PubMed ID: 22398318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved tuberculosis DNA vaccines by formulation in cationic lipids.
    D'Souza S; Rosseels V; Denis O; Tanghe A; De Smet N; Jurion F; Palfliet K; Castiglioni N; Vanonckelen A; Wheeler C; Huygen K
    Infect Immun; 2002 Jul; 70(7):3681-8. PubMed ID: 12065510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of biomarkers after intramuscular injection of Vaxfectin-formulated hCMV gB plasmid DNA.
    Vilalta A; Shlapobersky M; Wei Q; Planchon R; Rolland A; Sullivan S
    Vaccine; 2009 Dec; 27(52):7409-17. PubMed ID: 19735757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
    Hartikka J; Bozoukova V; Morrow J; Rusalov D; Shlapobersky M; Wei Q; Boutsaboualoy S; Ye M; Wloch MK; Doukas J; Sullivan S; Rolland A; Smith LR
    Hum Vaccin Immunother; 2012 Nov; 8(11):1595-606. PubMed ID: 22922766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization.
    Reyes L; Hartikka J; Bozoukova V; Sukhu L; Nishioka W; Singh G; Ferrari M; Enas J; Wheeler CJ; Manthorpe M; Wloch MK
    Vaccine; 2001 Jun; 19(27):3778-86. PubMed ID: 11395213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
    Sedegah M; Rogers WO; Belmonte A; Belmonte M; Banania G; Patterson N; Ferrari M; Kaslow DC; Carucci DJ; Richie TL; Doolan DL
    Vaccine; 2006 Mar; 24(11):1921-7. PubMed ID: 16298024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-lethal viral challenge of influenza haemagglutinin and nucleoprotein DNA vaccinated mice results in reduced viral replication.
    Cox RJ; Mykkeltvedt E; Robertson J; Haaheim LR
    Scand J Immunol; 2002 Jan; 55(1):14-23. PubMed ID: 11841688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epitope-specific cytotoxic T lymphocyte induction by minigene DNA immunization.
    Iwasaki A; Dela Cruz CS; Young AR; Barber BH
    Vaccine; 1999 Apr; 17(15-16):2081-8. PubMed ID: 10217610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.
    Lin WH; Vilalta A; Adams RJ; Rolland A; Sullivan SM; Griffin DE
    J Virol; 2013 Jun; 87(12):6560-8. PubMed ID: 23552419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.
    Doukas J; Morrow J; Bellinger D; Hilgert T; Martin T; Jones D; Mahajan R; Rusalov D; Sullivan S; Rolland A
    Vaccine; 2011 Jul; 29(33):5443-52. PubMed ID: 21641955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses.
    Cui Z; Mumper RJ
    Eur J Pharm Biopharm; 2003 Jan; 55(1):11-8. PubMed ID: 12551699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cationic influenza virosomes as an adjuvanted delivery system for CTL induction by DNA vaccination.
    Jamali A; Holtrop M; de Haan A; Hashemi H; Shenagari M; Memarnejadian A; Roohvand F; Sabahi F; Kheiri MT; Huckriede A
    Immunol Lett; 2012; 148(1):77-82. PubMed ID: 22981929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
    Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
    J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene vaccination with naked plasmid DNA: mechanism of CTL priming.
    Corr M; Lee DJ; Carson DA; Tighe H
    J Exp Med; 1996 Oct; 184(4):1555-60. PubMed ID: 8879229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.
    Smith LR; Wloch MK; Ye M; Reyes LR; Boutsaboualoy S; Dunne CE; Chaplin JA; Rusalov D; Rolland AP; Fisher CL; Al-Ibrahim MS; Kabongo ML; Steigbigel R; Belshe RB; Kitt ER; Chu AH; Moss RB
    Vaccine; 2010 Mar; 28(13):2565-72. PubMed ID: 20117262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmid DNA vaccines are effective in the absence of IFNgamma.
    Hassett DE; Zhang J; Whitton JL
    Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.